Newsletters
Everest Medicines Announces China NMPA Approval of VELSIPITY® for Adults with Moderately to Severely Active Ulcerative Colitis
[Everest Medicines] Everest Medicines announced that China's National Medical Products Administration (NMPA) has approved VELSIPITY® for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent.
Palmitic Acid Activates C-Myc via Dual Palmitoylation-Dependent Pathways to Promote Colon Cancer
[Cell Discovery] Researchers identified palmitic acid as a metabolite cue that activates c-Myc via dual palmitoylation-dependent pathways operating across tumor initiation and progression.
Acinetobacter Baumannii Promotes Gastric Cancer Metastasis via NA-Mediated NAD Metabolism Reprogramming and Glycolytic Activation
[Gut] Investigators elucidated the role of Acinetobacter baumannii in enhancing nicotinamide adenine dinucleotide (NAD) metabolism in gastric cancer (GC) cells through NA synthesis, consequently promoting GC metastasis.
E-Cadherin Loss in Cd44-Positive Gastric Cells Initiates Diffuse Gastric Cancer in a Murine Model
[Gut] Scientists aimed to develop mouse models of sporadic and hereditary diffuse gastric cancer (DGC) by inactivation of Cdh1 in the mouse stomach. They generated tamoxifen-inducible Cre/loxP mouse models of DGC driven by the Cd44 promoter with a tdTomato reporter.
Elovl6 Inhibits Colorectal Cancer Progression through Stearic Acid-Mediated Mitochondrial Fusion and Metabolic Reprogramming
[Science Advances] Researchers identified elongation of very-long-chain fatty acid protein 6 (Elovl6) as a critical regulator in colorectal cancer progression. Clinical data reveal significant down-regulation of Elovl6 in colon cancer tissues.
Metabolic Stress Conditions Dictate MAPKAPK2-Dependent Efficiency of MEK1/2 Inhibition in Colorectal Carcinoma
[Proceedings of the National Academy of Sciences of the United States of America] Investigators demonstrated that MAPKAPK2 protein levels in colorectal carcinoma regulate cell fate decision during stress conditions, such as glucose deprivation and therapeutic treatment.
UBE2M As a Bridge Spanning Neddylation and Cell Cycle Regulation in Colorectal Adenocarcinoma
[Experimental & Molecular Medicine] By leveraging single-cell and bulk transcriptome data, scientists demonstrated that neddylation is associated with G2M phase progression in colorectal cancer (CRC). They identified ubiquitin conjugating enzyme E2 M (UBE2M) as a molecular bridge spanning neddylation and the cell cycle in CRC.
A Nuclear Isoform of Hydroxyacyl-COA Dehydrogenase Inhibits Tumor Progression in Colorectal Cancer
[Iscience] The authors demonstrated that the human hydroxyacyl-CoA dehydrogenase gene, catalyzing the third step of the mitochondrial β-oxidation cascade, has two alternative translation start codons.
PLOD2 Promotes Proliferation, Migration, and Invasion of Colorectal Cancer Cells via PI3K-AKT-GSK3β Signaling Pathway
[Scientific Reports] Researchers identified a significant upregulation of PLOD2 in colorectal cancer (CRC). This upregulation was closely associated with clinical stage, lymph node metastasis, and nerve invasion in CRC.
Dietary Antigen Interaction with Intestinal Epithelial Cells
[Current Allergy and Asthma Reports] The authors summarize the current understanding of antigen transport across the intestinal epithelium in steady state and food-allergic conditions.
Regulatory T Cells Safeguard Liver Health during Metabolic-Associated Steatohepatitis
[Proceedings of the National Academy of Sciences of the United States of America] Multipronged data on a complementary pair of murine metabolic-dysfunction-associated steatohepatitis (MASH) models and published single-cell RNA-sequencing datasets from MASH patients revealed a critical protective role for Foxp3+CD4+ Tregs in MASH.
Adoptive γδ T Cell Therapy Controls Cytomegalovirus Infection in Preclinical Transplantation Models
[Nature Communications] Scientists assessed a Vδ1 + γδ T cell-based adoptive cell therapy, named Delta One T cells, to treat cytomegalovirus infection in high-risk transplant recipients.

Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
